Stockscreener 앱 받기
3.21
0.00%
0.00
Arbutus Biopharma Corp 주식(ABUS)의 최신 뉴스
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $754,000 in Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma's SWOT analysis: hepatitis B focus drives stock potential - Investing.com
Arbutus Biopharma (NASDAQ:ABUS) Shares Gap DownHere's Why - MarketBeat
Charles Schwab Investment Management Inc. Purchases 831,663 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
Intech Investment Management LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Large Shareholder Urges Warminster-based Arbutus to Seek Partners Instead of Selling More Stock - BUCKSCO.Today
Here’s Why Arbutus (ABUS) Surged in Q3 - Yahoo Finance
Arbutus Biopharma's SWOT analysis: focus on CHB treatment drives stock outlook - Investing.com
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors - The Bakersfield Californian
Arbutus Biopharma's HBV Trial Hits 50% Cure Rate; Major Investor Urges Strategic Partnership - StockTitan
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update - MarketBeat
Arbutus Biopharma (STU:I9DN) 9-Day RSI : 39.19 (As of Dec. 01, 2024) - GuruFocus.com
Principal Financial Group Inc. Reduces Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat - Yahoo Finance
Arbutus Biopharma (FRA:I9DN) Price-to-Operating-Cash-Flow : (As of Nov. 25, 2024) - GuruFocus.com
Arbutus Biopharma (STU:I9DN) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
Arbutus Biopharma (STU:I9DN) Long-Term Debt & Capital Lease Obligation : €0.88 Mil (As of Sep. 2024) - GuruFocus.com
Arbutus Biopharma (NASDAQ:ABUS) Earns "Buy" Rating from Chardan Capital - MarketBeat
HC Wainwright Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment - MyChesCo
Arbutus Biopharma Announces Positive Data from Clinical Trials at AASLD – The Liver Meeting® 2024 - Defense World
Promising New Data from Hepatitis B Trial by Arbutus and Barinthus - MyChesCo
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 16.0% in October - Defense World
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results - MyChesCo
Arbutus Biopharma to Showcase Innovations at Jefferies London Healthcare Conference - MyChesCo
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon - Yahoo Finance
Two Seas Capital LP Adjusts Stake in Arbutus Biopharma Corp - GuruFocus.com
Arbutus to Present at Jefferies London Healthcare Conference - Yahoo Finance
Creative Planning Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
HC Wainwright Has Negative Forecast for ABUS FY2024 Earnings - MarketBeat
HC Wainwright Expects Weaker Earnings for Arbutus Biopharma - Defense World
HC Wainwright Reaffirms “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Arbutus Biopharma 8-K Filing: Financial Results and Corporate Presentation Update - Defense World
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Earnings Call Transcript - Insider Monkey
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
HC Wainwright Reaffirms Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... By GuruFocus - Investing.com Canada
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Arbutus Fades on Q4 Results - Baystreet.ca
Arbutus Biopharma earnings missed, revenue fell short of estimates - Investing.com
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arbutus Biopharma Corp Q3 2024 Earnings: EPS Loss of $0.10 Meets Estimates, Revenue Falls Short at $1.3 Million - GuruFocus.com
Arbutus: Q3 Earnings Snapshot - San Francisco Chronicle
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Arbutus Biopharma (ABUS) Set to Announce Earnings on Wednesday - MarketBeat
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance
SG Americas Securities LLC Acquires New Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Target of Unusually High Options Trading (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma Corp (ABUS) Stock: A Year of Declines and Increases - The InvestChronicle
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 5.7%Still a Buy? - MarketBeat
2.88%
2.65%
자본화:
|
볼륨(24시간):